Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
2.153
-0.047 (-2.12%)
Mar 14, 2025, 11:39 AM EDT - Market open
Gain Therapeutics Revenue
In the year 2023, Gain Therapeutics had annual revenue of $55.18K, down -58.40%.
Revenue (ttm)
$55.18K
Revenue Growth
-58.40%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
32
Market Cap
57.12M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GANX News
- 3 hours ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 8 days ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
- 2 months ago - Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - GlobeNewsWire
- 3 months ago - Gain Therapeutics To Present At Biotech Showcase 2025 - GlobeNewsWire
- 5 months ago - Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 - GlobeNewsWire